What it sells
Control lab instruments with natural language.
Business model breakdown
Buyer: who owns the budget?
UnverifiedLab directors / heads of core facilities, diagnostic labs and production labs that run many protocols across different instruments (inferred from the FAQ on who they work with).
Trigger: what makes them buy now?
Lab staff burn time turning ambiguous written protocols into machine code for liquid handlers and other instruments; knowledge sits in individual heads and leaves when people leave.
Workflow: what inputs become what output?
Describe the experiment or upload a methods document, Infera compiles it into validated instrument instructions (collision and volume checks), a human reviews the preview, then the run is exported to the instrument with an audit trail.
Economics: what it saves and how it charges
Tiered pricing by lab size and usage, from small academic lab to production facility; no numbers published for the lab-automation product. Companion BioBase desktop agent app is credit-based.
Distribution: how it reaches customers
Pilot-led and founder-led: labs apply via an early-access form or book a 30-min call; Infera staff set up in the lab within a few weeks. Mostly Boston and Bay Area.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Spring 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.